Protagonist Therapeutics, Inc. (PTGX) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Protagonist Therapeutics is a biopharmaceutical company focused on peptide therapeutics for inflammatory/immunomodulatory diseases and hematology/blood disorders. The company operates as a single segment and is currently advancing two late-stage candidates: icotrokinra (licensed to Janssen/Johnson & Johnson) and rusfertide (co-developed with Takeda).
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| License & Collaboration Revenue | $4.7 million | $4.7 million | $38.6 million | $263.8 million |
| Net Loss | $(39.3) million | $(33.2) million | $(85.8) million | $143.5 million (Income) |
| Operating Expenses | $51.1 million | $46.1 million | $146.4 million | $137.7 million |
| Research & Development (R&D) | $40.0 million | $36.0 million | $112.9 million | $103.2 million |
| General & Administrative (G&A) | $11.1 million | $10.2 million | $33.4 million | $34.5 million |
| Interest Income | $7.0 million | $7.7 million | $22.0 million | $19.5 million |
| Cash, Cash Equivalents & Marketable Securities | $678.8 million (as of Sept 30, 2025) | |||
| Accumulated Deficit | $426.3 million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Decline: YTD revenue dropped 85% to $38.6 million compared to $263.8 million in the prior year. This is primarily due to the recognition of a $254.1 million upfront payment from the Takeda collaboration in Q1 2024, which is not recurring. Q3 2025 revenue was flat at $4.7 million, driven by development services.
- Net Loss vs. Income: The company reported a net loss of $85.8 million for the nine months ended Sept 30, 2025, compared to net income of $143.5 million in the same period in 2024. The prior year income was driven by the large Takeda upfront payment.
- R&D Expense Increase: R&D expenses increased 9% YTD to $112.9 million. This was driven by an $18.6 million increase in pre-clinical and drug discovery costs (specifically for new candidates PN-881 and PN-477), partially offset by a decrease in rusfertide Phase 3 costs following the completion of the VERIFY trial.
- Liquidity Position: Total cash and marketable securities increased to $678.8 million from $559.2 million at year-end 2024, bolstered by milestone payments received from Janssen ($165 million in Jan 2025) and Takeda ($25 million in Sept 2025).
Outlook, Management Commentary, and Risks
- Regulatory Milestones:
- Icotrokinra (Janssen): A New Drug Application (NDA) was submitted to the FDA in July 2025 and a Marketing Authorisation Application (MAA) to the EMA in September 2025 for plaque psoriasis. Janssen is responsible for commercialization.
- Rusfertide (Takeda): Received FDA Breakthrough Therapy designation in August 2025 for polycythemia vera (PV). The Phase 3 VERIFY trial met its primary endpoint. An NDA filing is expected by the end of 2025.
- Pipeline Updates: First human subject dosed in October 2025 for PN-881 (IL-17 antagonist). IND-enabling studies are underway for PN-477 (obesity triple agonist), with Phase 1 anticipated in 2026.
- Financial Outlook: Management expects revenue in 2025 to be significantly lower than 2024 due to the lack of large upfront payments. The company projects its current cash position will fund operations for at least the next 12 months.
- Risks:
- Government Shutdown: A U.S. federal government shutdown commenced in October 2025, creating uncertainty regarding FDA review timelines for pending NDAs.
- Macroeconomic Factors: Risks include high interest rates, geopolitical instability, and potential tariffs on pharmaceutical imports announced in September 2025.
- Capital Needs: While currently liquid, the company may need to raise additional capital to advance its early discovery pipeline and commercialize approved products.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $678.8 million cash balance against projected burn rates, especially given the expectation of lower revenue in 2025.
- Revenue Recognition: Confirm the timing of the remaining $17.0 million in deferred revenue from the Takeda agreement and the specific milestones triggering future payments.
- Regulatory Status: Monitor the impact of the October 2025 government shutdown on the FDA review of the icotrokinra NDA (submitted July 2025) and the anticipated rusfertide NDA (expected end of 2025).
- Milestone Payments: Track the achievement of the $50 million FDA approval milestone for icotrokinra and the $50 million (or $75 million if opt-out is exercised) milestone for rusfertide.
- R&D Spend Allocation: Assess the efficiency of the increased pre-clinical spending ($18.6 million increase YTD) on new candidates PN-881 and PN-477 relative to the progress of late-stage assets.